Metabolism and Disposition of Pacritinib (SB1518), an Orally Active Janus Kinase 2 Inhibitor in Preclinical Species and Humans.

Jayaraman, Ramesh

Metabolism and Disposition of Pacritinib (SB1518), an Orally Active Janus Kinase 2 Inhibitor in Preclinical Species and Humans. [electronic resource] - Drug metabolism letters 2015 - 28-47 p. digital

Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article

1874-0758

10.2174/1872312809666150119105250 doi


Administration, Oral
Animals
Biological Availability
Biotransformation
Bridged-Ring Compounds--administration & dosage
Cells, Cultured
Cytochrome P-450 CYP3A--metabolism
Dealkylation
Dogs
Feces--chemistry
Hepatobiliary Elimination
Hepatocytes--metabolism
Humans
Janus Kinase 2--antagonists & inhibitors
Liver--metabolism
Male
Metabolic Clearance Rate
Mice, Inbred BALB C
Mice, Nude
Microsomes, Liver--metabolism
Models, Biological
Oxidation-Reduction
Protein Binding
Protein Kinase Inhibitors--administration & dosage
Pyrimidines--administration & dosage
Rats
Rats, Wistar
Species Specificity
Tissue Distribution